Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited ...
Avirmax Inc. will deliver two scientific presentations at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, Colorado May 3 - 7, 2026. ARVO is the largest ...
NovaBridge Biosciences ( (NBP)) has issued an update. On April 7, 2026, NovaBridge Biosciences reported its full-year 2025 results, underscoring a strategic shift into a global biotech platform built ...
A rolling NDA has been initiated for tinlarebant in STGD1, potentially positioning the first disease-modifying systemic ...
The 42nd Annual Conference of the Syrian Society of Ophthalmologists opened in Damascus with the participation of more ...
Operation Clean Sweep (OCS), anindustry-led resin stewardship program, has unveiled its 2025 Global Impact Report, ...
The importance of experience becomes apparent early in medical training. Yet experience is shaped not only by time—it is also ...
Ferris State equips students with advanced tools and skills for plastics manufacturing through industry collaboration and ...
Regeneron rebounds from regulatory and clinical setbacks as Dupixent and pipeline catalysts fuel growth. Click here to read ...
The all-cash deal adds more than 120 assets to Ligand's portfolio and is expected to close in the third quarter of 2026 ...
Theialife, a late-stage clinical company advancing innovative therapeutic solutions for ocular diseases, today announced the appointment of Thomas Ruggia as President and Chief Executive Officer. Mr.
Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical treatment for diabetic macular edema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results